Muhammet Tanc
Seminars
Thursday 3rd December 2026
Targeting Therapy-Resistant Cancer with Radiotheranostics: Preclinical Insights from ALDH1A1- Directed Development
11:00 am
- Presenting preclinical data supporting the development of ALDH1A1-targeted radiotheranostics in therapy-resistant cancers
- Exploring the rationale for targeting resistance-associated biology and assessing its potential to address unmet clinical need
- Evaluating the translational challenges associated with advancing novel intracellular targets toward clinical development
Wednesday 2nd December 2026
Beyond Regulatory Requirements: Maximising the Value of Toxicology Studies to De-Risk Preclinical Development
2:15 pm
- Understanding the critical role of toxicology studies in supporting safe and successful radiopharmaceutical development
- Exploring how developers can generate additional translational insights from toxicology programmes beyond minimum regulatory requirements
- Examining the unique considerations associated with designing and interpreting toxicology studies for radiopharmaceuticals
